VAL Share PerformanceMore
|52 week high||11.4900 04/10/16|
|52 week low||2.0600 05/04/17|
|52 week change||-7.6000 (-76.00%)|
|4 week volume||14,643,545 01/05/17|
Media for (VAL)
Latest News« previous» nextMore
24/05/2017 - 07:40 StockMarketWire
ValiRx reported that ValiSeek, the joint venture between ValiRx and Tangent Reprofiling, received notification that an Au...
24/05/2017 - 07:00 RNS
RNS Number: 0240G ValiRx PLC 24 May 2017 ValiRx Plc ("ValiRx" or the "Company") NOTIFICATION OF AUSTRALIAN PATENT ALLOWANCE FOR THERAPEUTIC COMPOUND, VAL401 London, UK ., 24 May 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased to report that ValiSeek Limited ("ValiSeek"), the joint venture...
08/05/2017 - 10:20 StockMarketWire
Beaufort Securities today reaffirms its speculative buy investment rating on ValiRx PLC (LON:VAL) and set its price targ...
08/05/2017 - 00:00 BRR Media
05/05/2017 - 17:28 RNS
RNS Number: 3902E ValiRx PLC 05 May 2017 ValiRx Plc ("ValiRx" or the "Company") Posting of Annual Report and Accounts & Notice of Annual General Meeting London, UK, 5 May 2017: ValiRx Plc (AIM: VAL) is a life science company with a focus on cancer therapeutics and diagnostics for personalised medicine. The Company announces that its Annual Rep...
05/05/2017 - 07:46 StockMarketWire
ValiRx has widened its FY pretax loss from continuing operations to 5.8m, which was more than double the prior year's lo...
05/05/2017 - 07:00 RNS
RNS Number: 2546E ValiRx PLC 05 May 2017 VALIRX PLC ("ValiRx", "the Company" or "the Group") FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2016 London, UK, 5 May 2017: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer therapeutics and diagnostics for personalised medicine, today announces its final results for the ...
27/04/2017 - 10:07 RNS
RNS Number: 5389D ValiRx PLC 27 April 2017 VALIRX PLC ("ValiRx", "the Company") Re: The SHARES Magazine Supplement " ValiRx And The Drug Development Journey", is now available on the ValiRx website London, UK., 27 April 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased to report that a recent supplement on the ...
|Dividend yield||0 %|
Equity Research (VAL)
V22 is an enterprise that showcases the wealth of talent in contemporary art. It has built a broad portfolio of around 150 artworks of living artists from around the world, paying in a mix of cash...
Latest discussion posts More
“you have very interesting proposal for val, i wonder if u can contact me on advfn (same id) by sending a message i would like to invite you to join other LTH members who r on ...”▼
“JG post of LSE compacted and posted here and sent to VIP investors in value to move thing along with other unpublished ...”▼
“There are a number of disclosures in the accounts worthy of comment in addition to those mentioned in my earlier post. Firstly, good to see that the Directors have suffered ...”▼
Codes & Symbols
|Symbols||VAL, LSE:VAL, VAL.L, VAL:LN, LON:VAL, XLON:VAL|